Cover Image

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Marta Paula Pereira Coelho, Thais Pontello de Vries, Aline Marcos Pires, Milena Pereira Parreira, Érika Ramos de Alvarenga, Rodrigo Dias Cambraia, Rodrigo Ribeiro dos Santos, Juliana Maria Trindade Bezerra, Enrico Antonio Colosimo, Gifone Aguiar Rocha, Luciana Diniz Silva
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Hepatitis C virus eradication improves skeletal muscle mass
by: Catherine Jia Lin Tian, et al.
Published: (2024)

Editorial: Quantity is important! Authors' reply
by: Marika Rudler, et al.
Published: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
by: Kyle Staller, et al.
Published: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
by: Kyuwon Kim, et al.
Published: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
by: Carolin V. Schneider, et al.
Published: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
by: Benedikt Silvester Hofer, et al.
Published: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
by: Stephanie A. Vuijk, et al.
Published: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
by: Nina Løn, et al.
Published: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
by: Annalisa Schiepatti, et al.
Published: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
by: Matthias Lenfant, et al.
Published: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
by: Dipesh H. Vasant, et al.
Published: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
by: Abhinav Vasudevan, et al.
Published: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
by: Matthias Lenfant, et al.
Published: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
by: Elliot B. Tapper, et al.
Published: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
by: Jessica A. Fitzpatrick, et al.
Published: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
by: Linda Henry, et al.
Published: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
by: Lana Bridi, et al.
Published: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
by: Mikkel Malham, et al.
Published: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
by: R. M. Mathias, et al.
Published: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
by: Jessica A. Fitzpatrick, et al.
Published: (2024)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
by: Marcus M. Mücke, et al.
Published: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
by: Hsin‐Che Lin, et al.
Published: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply
by: Rocío Ferreiro‐Iglesias, et al.
Published: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
by: Tomohiro Fukuda, et al.
Published: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
by: Hyeyeon Hong, et al.
Published: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
by: Manya Prasad, et al.
Published: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
by: María José García, et al.
Published: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
by: Akshatha Kiran, et al.
Published: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
by: Stuart McPherson, et al.
Published: (2024)

Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply
by: Tarek Hassanein, et al.
Published: (2024)

Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply
by: Maria Gabriela Fernandes Dezan, et al.
Published: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice. Authors' reply
by: Eunice X. X. Tan, et al.
Published: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
by: Samer Gawrieh, et al.
Published: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
by: David Bergman, et al.
Published: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
by: Lukas Burghart, et al.
Published: (2024)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
by: Ami D. Sperber, et al.
Published: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
by: Arta Aliu, et al.
Published: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
by: Francisco Idalsoaga, et al.
Published: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
by: Remo Panaccione
Published: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
by: María José García, et al.
Published: (2024)